Sutro Biopharma tops 2025 revenue estimates

Sutro Biopharma

23/03/2026 20:18

Overview

US clinical-stage oncology firm's 2025 revenue rose, beating analyst expectations

Net loss narrowed yr/yr as operating expenses declined after restructuring

Company raised $110 mln, extending cash runway into at least Q2 2028

Outlook

Sutro expects its cash runway to extend into at least Q2 2028

Result Drivers

COLLABORATION REVENUE - 2025 revenue increase was principally due to collaboration and license revenue from Astellas and Ipsen partnerships

MILESTONE PAYMENTS - Advancement of Astellas-partnered programs triggered milestone payments, contributing to revenue

Total R&D and G&A expenses for the year ended December 31, 2025 were $207.4 million, as compared to $300.5 million for the year ended December 31, 2024

Company press release: ID:nGNX7t5ZNm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
$102.48 mln
$99.19 mln (10 Analysts)
FY Net Income
-$191.09 mln
FY Operating Expenses
$260.85 mln
FY Operating Income
-$158.37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sutro Biopharma Inc is $23.00, about 11.2% above its March 20 closing price of $20.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)